论文部分内容阅读
目的:探讨转录因子T-bet/GATA-3在哮喘发病中的作用机理,分析以T-bet/GATA-3为靶标的哮喘治疗手段。方法:总结近10年关于T-bet/GATA-3在哮喘发病中的机理研究及以此为靶标治疗哮喘的相关文章,进行分析、归纳。结果:T-bet/GATA-3作为哮喘发病中的转录因子,能够客观地反映Th1/Th2细胞分化和Th1型细胞因子、Th2型细胞因子的变化。以其为靶标治疗哮喘的方式近年取得的进展主要有生物制剂、免疫疗法、中医药、以及神经生长因子、寡核苷酸、转录因子圈套策略等分子和基因水平的治疗方法。结论:以转录因子T-bet/GATA-3为靶标的哮喘治疗手段近年取得较多进展,提示在转录水平将Th0细胞向Th1/Th2细胞分化这个环节作为治疗疾病的靶点,可能成为延长哮喘缓解期、减少复发的关键。
Objective: To explore the mechanism of transcription factor T-bet / GATA-3 in the pathogenesis of asthma and analyze the treatment of asthma with T-bet / GATA-3 as the target. Methods: The recent 10 years on the T-bet / GATA-3 in the pathogenesis of asthma in the pathogenesis and as a target for the treatment of asthma related articles, analyzed and summarized. Results: T-bet / GATA-3 as a transcription factor in the pathogenesis of asthma can objectively reflect the changes of Th1 / Th2 cell differentiation, Th1 type cytokines and Th2 type cytokines. Recent advances in the treatment of asthma using it as a target include the treatment of biological agents, immunotherapy, Chinese medicine, and molecular and genetic levels of nerve growth factor, oligonucleotide and transcription factor trapping strategies. Conclusion: The progress made in the treatment of asthma with the transcription factor T-bet / GATA-3 as the target has made more progress in recent years, suggesting that the differentiation of Th0 cells into Th1 / Th2 cells at the transcriptional level may serve as a target for the treatment of asthma and may prolong asthma Remission, reduce the key to relapse.